Day Zero secures $8.2 million in strategic investment
Day Zero is an infectious disease diagnostic technology developer in the United States, dedicated to the development of Blood2Bac (a method for extracting bacterial DNA from clinical samples). In addition to this, the company has established a large database, Micro hmDB, which contains the whole genome sequences of pathogens and their resistance to antibiotics. Recently, […]
Day Zero secures $8.2 million in strategic investment Read More »